Chemo during pregnancy not detrimental

Article

Despite the occurrence of more neonatal and obstetrical events in women receiving chemotherapy during pregnancy than in those who wait until after, a recent study in the online edition of the August 16, 2012 Lancet Oncology finds the differences clinically insignificant. Researchers say that differences in outcomes are more the result of premature delivery than they are of chemotherapy.

Despite the occurrence of more neonatal and obstetrical events in women receiving chemotherapy during pregnancy than in those who wait until after, a recent study in the online edition of the August 16, 2012 Lancet Oncology finds the differences clinically insignificant. Researchers say that differences in outcomes are more the result of premature delivery than they are of chemotherapy.

After adjusting for gestational age, the researchers found that birth weight was affected by chemotherapy exposure, but not by number of cycles. They also found no statistical difference between the 2 groups for premature deliveries before the 37th week. About half of the women delivered preterm, about one-quarter of whom delivered before the 35th week. In comparison, about 10% to 15% of all infants are born before the 37th week of gestation. In this study, preterm delivery was more common in women who delayed chemotherapy than in those who began treatment while pregnant.

Ten percent of the infants born had side effects, malformations, or newborn complications consistent with those seen in the general population. These events were about 3 times as common in the infants born before 37 weeks’ gestation as in those born later. Adverse events were about 4 times more common in the women who received chemotherapy during pregnancy than among those who didn’t. The researchers believe that most of the malformations were a result of premature delivery and not chemotherapy exposure because malformations occur only during the first trimester and the chemotherapy was administered in other trimesters.

Interestingly, taxanes are generally not recommended for use during pregnancy, but this study showed no difference in complications in infants exposed to those drugs versus other forms of chemotherapy.  

The study appeared in the online edition of the Lancet Oncology.

Read other articles in this issue of Special Delivery.

Recent Videos
Revi System shows efficacy against urgency urinary incontinence | Image Credit: ics.org.
1 expert is featured in this series.
Researchers highlight risks of breastfeeding while taking Levetiracetam | Image Credit: uwaterloo.ca.
Ipek Ensari, PhD, highlights improved mental health in chronic pelvic pain from physical activity | Image Credit: scholars.mssm.edu
New pSNM system empowers patients in urge urinary incontinence treatment | Image Credit: trinityhealthmichigan.org.
Jannah Thompson, MD, highlights battery free device for UUI management | Image Credit: trinityhealthmichigan.org
Anietie Aliu, PhD, highlights racial barriers to breast cancer screening | Image Credit: bbc.com.
Anietie Aliu, PhD, discusses how to improve breast cancer screening disparities | Image Credit: bbc.com
Jennifer Payne, MD, highlights how to help young women with perimenopause symptoms | Image Credit: uvahealth.com/findadoctor.
Perimenopausal symptoms in young women discussed by Jennifer Payne, MD | Image Credit: uvahealth.com/findadoctor.
Related Content
© 2025 MJH Life Sciences

All rights reserved.